Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Exp Neurol. 2012 Sep 26;239:38–48. doi: 10.1016/j.expneurol.2012.09.012

Figure 2. Spatial and temporal distribution of the proliferating cells and their fate in the hippocampus one week after TBI.

Figure 2

(a) Quantification of the proliferating cells in the hippocampus after traumatic brain injury (TBI) and their spatial and temporal distribution (n=5). * p<0.05; ** p<0.001; *** p<0.0001. (b) Double immunostaining with anti-BrdU (red) and anti-GFAP (green) antibodies to identify proliferating astrocytes in the injured hippocampus. (c) Double immunostaining with anti-BrdU (red) and Iba1 (green) antibodies to identify proliferating microglia in the injured hippocampus. (d) Double immunostaining with anti-BrdU (red) and anti-nestin (green) antibodies to identify proliferating neural stem/progenitor cells (NSCs) in the injured hippocampus. (e) Immunostaining with anti-BrdU (red) to identify proliferating cells in the hippocampal dentate gyrus (HDG) of nestin-EGFP transgenic mice after sham treatment. (f) Immunostaining with anti-EGFP (green) to identify EGFP expressing NSCs in the HDG of nestin-EGFP transgenic mice after sham treatment. (g). Merged image of (e) and (f). The BrdU and EGFP double-positive cells are pointed out by white arrows. (h) Immunostaining with anti-BrdU (red) to identify proliferating cells in the hippocampal dentate gyrus of nestin-EGFP transgenic mice after TBI. (i) Immunostaining with anti-EGFP (green) to identify EGFP expressing NSCs in the HDG of nestin-EGFP transgenic mice after TBI. (j). Merged image of (h) and (i). The BrdU and EGFP double-positive cells are pointed out by white arrows. The BrdU+ positive cells without expressing EGFP are pointed out by white arrowheads.